BMY vs. GILD

In the year-to-date period, BMY achieves a -13.45% return, which is significantly lower than GILD's 12.48% return. Over the past 10 years, BMY has underperformed GILD with an annualized return of 0.23%, while GILD has yielded a comparatively higher 3.45% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMY Sharpe Ratio is 0.08, which is lower than the GILD Sharpe Ratio of 2.39. The chart below compares the historical Sharpe Ratios of BMY and GILD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BMY's dividend yield for the trailing twelve months is around 5.09%, more than GILD's 3.00% yield.

The maximum BMY drawdown since its inception was -70.62%, roughly equal to the maximum GILD drawdown of -70.82%. Use the drawdown chart below to compare losses from any high point for BMY and GILD. For additional features, visit the drawdowns tool.

Bristol-Myers Squibb Company (BMY) has a higher volatility of 9.92% compared to Gilead Sciences, Inc. (GILD) at 8.79%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than GILD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Gilead Sciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.